We have unceasingly strived to realize our corporate philosophy of always making a contribution to human health.
Kyorin will continue to take on challenges and will evolve to become a company supporting healthy lifestyles through our business in the treatment and prevention of disease and the maintenance and promotion of good health.
- The purple border isCompany history
- The orange border isProduct history
Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.
Kyorin Chemical Laboratory was established.
Kyorin Chemical Laboratory was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.
The Okaya Plant was started.
The medical journal bulletin “Doctor Salon” was started.
Behyd, a diuretic and antihypertensive agent, was launched.
Kyorin Chemical Laboratory (later Technical Center of Development) was established.
The Head Office was completed in Kanda Surugadai.
KYORIN AP-2, an analgesic, was launched.
Deamelin-S, an oral hypoglycemic agent, was launched.
The Nogi Plant was opened.
Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.
Hespander, a plasma substitute and extracorporeal circulation flow improver, was launched.
Central Research Laboratories were opened.
Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co. (U.S.A.).
Mucodyne, a mucoregulant, was launched.
Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.
Ketas, for bronchial asthma and cerebrovascular disorders, was launched.
Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.
KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.
Megalocin (FLRX), a long-acting new quinolone agent, was launched.
The Noshiro Plant was opened.
A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.
The Research Center (now the WATARASE Research Center) was founded.
Pentasa, a treatment for ulcerative colitis and Crohn’s disease, was launched.
Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).
Milton, an effervescent disinfectant business, was acquired from P&G.
Listed on the Tokyo Stock Exchange, Second Section.
Listed on the Tokyo Stock Exchange, First Section.
Gatifloxacin eyedrops was licensed to Allergan (U.S.A.).
A subsidiary company, Kyorin USA, Inc. (U.S.A.), was established.
Kipres, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
A subsidiary company, Kyorin Europe GmbH (Germany), was established.
Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.
ActivX Biosciences, Inc. (U.S.A.) became a wholly owned subsidiary.
The stock of Toyo Pharma Co., Ltd. (present KYORIN Rimedio Co., Ltd.) was acquired, making it into a subsidiary company.
The Nogi Plant was closed.
The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.
Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.
KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.
KYORIN Co., Ltd. changed its name to KYORIN Holdings, Inc.
Acquisition (conversion into subsidiary) of the Shiga Plant of MSD K.K. and established KYORIN Pharmaceutical Facilities Co., Ltd.
RUBYSTA, a multi-purpose disinfectant cleaner, was launched.
Head office moved to Ochanomizu sola city in Kanda Surugadai.
Flutiform, a combination drug for asthma treatment, was launched.
Establishment of the WATARASE Research Center of KYORIN Pharmaceutical Co., Ltd. through consolidation of the Drug Discovery Center (the former Central Research Laboratories) and the R&D Center (the former Research Center).
Eklira Genuair, a treatment for COPD, was launched.
FPR2 agonist program was licensed to Bristol-Myers Squibb Company (U.S.A.)
The Okaya Plant was closed
Montelukast tablets 10mg, 5mg「KM」, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.
DESALEX Tablets 5mg a treatment of allergic diseases drug was launched売
KYORIN Rimedio Co., Ltd.’s Takaoka Pharmaceutical Technology Innovation Center was established.
New manufacturing subsidiary, KYORIN Pharmaceutical Group Facilities Co., Ltd. (head office: Tokyo), commences operations.
Beova Tablets 50mg a treatment of OAB drug was launched.
GeneSoC®, a microchannel-based genetic measurement device, was launched.
KYORIN Pharmaceutical Group Facilities Co., Ltd. and KYORIN Medical Supply Co., Ltd. merge.
Lasvic Tablets 75mg an oral quinolone antibacterial agent was launched.
Lasvic Intravenous Drip Infusion Kit 150mg an injectable new quinolone antibacterial agent was launched.
Zymso Intravesical Solution 50%, an interstitial cystitis treatmet was launched.
GeneSoC® mini was launched.
Lyfnua® Tablets 45mg Selective P2X3 receptor antagonist/Refractory chronic cough was launched.
ActivX Biosciences, Inc. was dissolved.
KYORIN Holdings, Inc. changed its trade name to KYORIN Pharmaceutical Co., Ltd. through absorption type merger of KYORIN Pharmaceutical Co., Ltd.